<DOC>
	<DOCNO>NCT01184456</DOCNO>
	<brief_summary>Improvement rate bacterial translocation may lead decrease chronic inflammatory response thereby decrease CD4 destruction HIV proliferation . By addition probiotic hope show reduction LPS lead decrease chronic inflammation therefore improvement immune marker .</brief_summary>
	<brief_title>A Controlled Trial Evaluate Effects GanedenBC30 Immune System</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Patient male nonpregnant , nonlactating female . Adults 18 year old . Is able provide write , inform consent participate study . Serological documentation HIV infection time prior study entry clinically stable . Stable CD4 count great equal 250 cells/cubic mm six month prior study entry ( +/ 50 cells/cubic mm ) . HIV1 RNA ≤50 copies/mL six month prior study entry . Karnofsky performance status 60 % . Adequate laboratory parameter within last 30 day : 1. absolute neutrophil count &gt; 1000 cells/cubic mm 2. hemoglobin &gt; 9.0 g/dL 3. platelet &gt; 75,000/cubic mm 4. creatinine &lt; 1.5 x upper limit normal 5 . SGOT/SGPT &lt; 3.0 x upper limit normal 6. bilirubin &lt; 2.0 mg/dL Patients document GI symptom include limited : flatulence , diarrhea , bloating , gastroesophageal reflux disease , nausea , constipation . If female childbearing potential , must practice effective method contraception agree use birth control protocol 1 month completion study . Women Child Bearing Potential ( WOCBP ) must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 72 hour prior start study medication . WOCBP include female experienced menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation bilateral oophorectomy ) . postmenopausal [ define amenorrhea 12 consecutive month ; woman hormone replacement therapy ( HRT ) document serum follicle stimulate hormone ( FSH ) level &gt; 35 mIU/mL ] . Even woman use oral , implanted , injectable contraceptive hormone mechanical product intrauterine device barrier method ( diaphragm , condom , spermicide ) prevent pregnancy practice abstinence partner sterile ( e.g. , vasectomy ) , consider child bear potential . Must agree practice protect sexual activity ( via barrier method ) course study . In opinion investigator , willing able comply study requirement . Active opportunistic infection , progressive , imminently disable life threatening , judgment Principal Investigator exception Kaposi Sarcoma . Cytotoxic chemotherapy , interferon treatment , radiation therapy within precede 3 week ( subject receive intralesional chemotherapy exclude , however ) . Any antibiotic therapy within 30 day enrollment Any probiotic formulation within 30 day enrollment Any immunization within 30 day enrollment Known history allergic reaction investigational product ingredient . Chronic treatment immunosuppressant drug , include corticosteroid , except treatment adrenal insufficiency . Topical steroid permit . History known current malabsorption syndrome . Any grade 3 4 lab abnormality define standardized grade scheme base DAIDS table ( see Appendix B ) follow exception : Preexisting diabetes glucose toxicity elevation ≥ grade 3 Triglyceride total cholesterol elevation ≥ grade 3 Clinical laboratory evidence clinically significant liver impairment/ dysfunction , disease cirrhosis . Life expectancy &lt; 6 month opinion investigator . Active substance abuse significant psychiatric illness opinion investigator might interfere study compliance . Female subject childbearing potential use effective nonhormonal birth control method willing continue practice birth control method screen last trial related activity . Subject pregnant lactating . Any condition Principal Investigator 's opinion may render subject unable complete study may pose significant risk subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>AIDS</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>HIV</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
</DOC>